Clinical Trial Update: Study of ILX651 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of ILX651 for locally advanced or metastatic non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ILX651

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Non-Small-Cell Lung Carcinoma | Phase 2 | Status: COMPLETED